
Heart failure specialists and the advanced practice providers who support them are often an important component of the multidisciplinary team management of obstructive hypertrophic cardiomyopathy (oHCM). The evolution of severe HF (NYHA functional class III or IV) occurs in at least 10–20% of patients with oHCM. While these symptoms can occur at any age, they are most frequently seen in middle-aged adults. Women tend to have more severe symptoms of HF occurring later in life, and like many cardiovascular syndromes, oHCM is often underrecognized in women. The risk of HF is augmented by the presence and degree of outflow tract obstruction. Further risk factors of HF include the presence of AF and diastolic dysfunction, though noninvasive measures do not reliably predict LV filling pressures in HCM, further complicating an early diagnosis. HF related to oHCM is unlikely to respond satisfactorily to treatment that does not target the pathophysiology of HCM.
Heart failure specialists should have a comprehensive understanding of oHCM—a complex cardiac condition—to ensure optimal management and improve patient outcomes. The global experts in this program will review the key elements of recognition, confirmation, and management of oHCM in the setting of HF.
Heart failure specialists and their supporting APPs, other cardiologists and internists, hospitalists, and PCPs who manage patients with HF and with HCM
Examine the epidemiology, pathophysiology, and clinical presentation of oHCM in order to recognize and diagnose HCM accurately and in a timely manner
Analyze the most up to date diagnostic criteria and techniques in order to diagnose HCM accurately and in a timely manner
Evaluate current evidence-based, targeted treatments for oHCM, including CMIs, in order to update treatment plans and improve outcomes in patients with HCM
Incorporate practical application strategies for following evidence-based recommendations from guidelines for oHCM management in order to improve outcomes in patients with HCM
Epidemiology and Unmet Needs of oHCM in the General Population – How Common is Heart Failure?
Pathophysiology and Rationale for CMIs in HCM and HFpEF
Maximizing Targeted Medical Therapy for oHCM: From Trials to Real World
Case: Challenging Choice Between CMIs and Surgery
Summary
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty
have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.
| Faculty | Relationship Identified With: |
| Iacopo Olivotto, MD (Course Chair)
|
Consultant/Advisor: Amicus Therapeutics, Inc; Bristol Myers Squibb; Cytokinetics; Genzyme Corporation; Rocket Pharmaceuticals, Inc.; Takeda Pharmaceuticals; Tenaya Therapeutics |
| Christoph Maack, MD
|
Consultant/Advisor: AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Eli Lilly and Company; Novo Nordisk A/S
Speaker’s Bureau: AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Diaplan; Eli Lilly and Company; Novo Nordisk A/S |
| Michelle Michels, MD | Consultant/Advisor: Alnylam Pharmaceuticals, Inc.; AstraZeneca; Bayer AG; Cytokinetics; Imbria; Sanofi
Grant/Research Support: Bristol Myers Squibb; Cytokinetics Speaker’s Bureau: Pfizer Inc. |
| Gianluigi Savarese, MD | Consultant/Advisor: Abbott; Edwards Lifesciences Corporation; F. Hoffmann-La Roche Ltd.; Getz Pharma; Hikma Pharmaceuticals; Intas Pharmaceuticals Ltd.; Teva Pharmaceutical Industries Ltd.; The Menarini Group
Grant/Research Support: AstraZeneca; Bayer AG; Boehringer Ingelheim International GmbH; Boston Scientific; CSL Vifor; Cytokinetics; Pharmacosmos A/S; Medtronic; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Servier Pharmaceuticals |
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC, Nicole McMenamin and Chelsey Simonds hereby state that they do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Participants should claim only the credit commensurate with the extent of their participation in the activity.
Through an agreement between the American Medical Association and the Union Européenne des Médecins Spécialistes, physicians may convert AMA PRA Category 1 Credit™ to an equivalent number of European CME Credits® (ECMECs®). These credits will be recognized by all National Accreditation Authorities in Europe with which the UEMS has a signed agreement of recognition of credits.
This activity has been supported by an independent educational grant from Bristol Myers Squibb.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Bristol Myers Squibb do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
For all CE inquiries or special needs, please contact admin@academiccme.com.
811 S. Orleans Ave. Tampa, Fl 33606